With over 200,000 opioid-related deaths in the U.S. alone, the Sackler family has come under intense scrutiny for their role ...

An investigation into the agency’s repeated violations of its own rules to approve addictive drugs—and its ongoing failure to ...

Harris unmistakably exposes Johnson & Johnson as a longtime corporate scoundrel, as harmful to public welfare as was its ...

COLUMN. Two economists have sought to determine the impact of the opioid crisis in the US. They found that in areas hit hard ...

The Lurie small-ball approach, making tiny steps and using the new San Francisco billionaire class as his ally, has split the ...

The UNC Health system announced Tuesday its CEO and the UNC School of Medicine's dean Dr. Wesley Burks will step down on Sept ...

Kaitlyn Dever sat down for an interview with the British magazine New Musical Express (NME), published on November 11, 2021.

NEW WESTMINSTER, B.C. — Conservative Leader Pierre Poilievre announced Sunday that he will fund centre-based addictions care ...

Joshua Jamerson is the The Wall Street Journal's deputy politics editor, based in Washington.

John McNerney was told his Purdue Pharma claim didn't qualify, because he hadn't been prescribed enough OxyContin to meet the threshold. He submitted claims for Mallinckrodt and Endo instead.

In the final installment of this series, advisers share the lessons they now apply to their healthcare and sales strategies.